TipRanks on MSN15h
Oric Pharmaceuticals Expands Equity Incentive Plan for Growth
Oric Pharmaceuticals ( ($ORIC) ) has provided an announcement. On March 11, 2025, Oric Pharmaceuticals’ Board of Directors approved an amendment ...
ORIC Pharmaceuticals (ORIC) Projected to Post Quarterly Earnings on Monday
ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report) is expected to post its quarterly earnings results before the market ...
Yahoo Finance7d
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing ...
ETF Daily News7d
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $18.86 Consensus PT from Brokerages
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) has received an average rating of “Buy” from the nine brokerages that are currently covering the company, Marketbeat reports.
Yahoo Finance24d
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that ...
Nasdaq24d
ORIC Pharmaceuticals Reports Promising Early Data for ORIC-944 and ORIC-114; Collaborates with Johnson & Johnson on NSCLC Treatment
ORIC Pharmaceuticals, Inc. announced positive early safety and efficacy results from its ongoing dose escalation trial of ORIC-944, combined with androgen receptor inhibitors for metastatic ...
Morningstar29d
ORIC Pharmaceuticals Inc
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Business Insider24d
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC Entered into clinical ...
manilatimes24d
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC Entered into clinical trial ...
Morningstar24d
ORIC Pharmaceuticals Inc
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
The Bakersfield Californian25d
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and ...
Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC Entered into clinical ...